ARKG Holdings of Pluristem Therapeutics Inc. (PSTI) - Updated Daily
TherapeuticsStem Cells
Key Statistics
Statistics
| ⚖️Weighting | 🧢Market Cap |
|---|---|
| 0% | $80.81m |
| 🏋🏿♂️Weight Rank In ARKG | 🌏Country |
| 59 | 🇮🇱Israel |
| 🏋️♀️Weight Rank Across All Funds | 💳ARK Estimated Cost Average |
| 244 | $11.20 |
| 🎫ARK Ownership Percent | |
| 0% | |
| Description | |
|---|---|
| Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late-stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off- the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a | |
| Website | |
| www.pluristem.com |